Department of Surgery, Southwestern Academic Limb Salvage Alliance, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Grunberger Diabetes Institute, Bloomfield Hills, MI, USA.
J Diabetes Sci Technol. 2023 Sep;17(5):1387-1391. doi: 10.1177/19322968221099542. Epub 2022 Jun 30.
Painful diabetic neuropathy (PDN) is a progressive condition that deprives many patients of quality of life. With limited treatment options available, successful pain management can be difficult to achieve.
We reviewed results of recent data evaluating high frequency spinal cord stimulation (SCS).
from the SENZA-PDN randomized clinical trial (NCT03228420), the largest such trial to date, demonstrated 10-kHz spinal cord stimulation substantially reduced PDN refractory to conventional medical management along with improvements in health-related quality-of-life measures that were sustained over 12 months. These data supported the recent U.S. Food & Drug Administration (FDA) approval for 10-kHz SCS in PDN patients and contributed to the body of evidence on SCS available to health care professionals managing the effects of PDN.
High frequency spinal cord simulation appears to hold promise in treatment of painful diabetic neuropathy. We look forward to future works in the literature that will further elucidate these promising findings.
痛性糖尿病周围神经病变(PDN)是一种进行性疾病,使许多患者丧失生活质量。由于治疗选择有限,成功的疼痛管理可能难以实现。
我们回顾了最近评估高频脊髓刺激(SCS)的数据结果。
来自 SENZA-PDN 随机临床试验(NCT03228420),这是迄今为止最大的此类试验,表明 10-kHz 脊髓刺激显著减轻了对常规医学管理有抗药性的 PDN,同时改善了健康相关生活质量的衡量标准,这些改善在 12 个月内持续存在。这些数据支持美国食品和药物管理局(FDA)最近对 PDN 患者的 10-kHz SCS 批准,并为管理 PDN 影响的医疗保健专业人员提供了有关 SCS 的现有证据。
高频脊髓模拟似乎在治疗痛性糖尿病周围神经病变方面有希望。我们期待未来文献中的进一步研究将阐明这些有前途的发现。